NAD+ (nicotinamide adenine dinucleotide) is the central redox cofactor in mitochondrial energy metabolism and sirtuin signaling. Systemic NAD+ declines with age, driving interest in injectable NAD+, IV infusions, and oral precursors like nicotinamide riboside (NR). Topical NAD+ face creams represent a parallel track: delivering the cofactor directly to the epidermis and dermis for photoaging, barrier repair, and local cellular energetics without a needle.

Compounded NAD+ pump creams at concentrations around 10% appear in pharmacy menus and med-spa formularies. The scientific logic is sound at the tissue level, skin cells require NAD+ for DNA repair, circadian regulation, and stress responses, but published human RCT data for high-concentration topical NAD+ specifically are thinner than the injectable and oral precursor literatures.

Why skin cares about NAD+

Keratinocytes and fibroblasts are metabolically active. UV radiation depletes NAD+ through PARP activation during DNA damage repair. Aging reduces NAD+ biosynthesis enzymes (NAMPT) in skin tissue. Lower NAD+ impairs sirtuin 1 and 6 activity, which regulate inflammation, collagen maintenance, and senescence markers in dermal cells.

Topical application aims to raise local NAD+ pools so skin can run repair programs without waiting for systemic supplementation to distribute through circulation. Whether NAD+ itself penetrates deeply enough at cosmetically relevant concentrations, versus working primarily in the stratum corneum and upper epidermis, depends on formulation vehicle.

Topical vs. injectable vs. precursors

Injectable NAD+ raises circulating pools rapidly; skin benefits may be secondary to systemic effects. Oral NR or NMN raises blood NAD+ metabolites over hours to days; skin receives supply through perfusion. Topical NAD+ targets local concentration at the application site with minimal systemic exposure, attractive for patients who want facial-specific anti-aging without whole-body protocols.

These routes are complementary, not mutually exclusive. A patient on injectable NAD+ may still use topical cream for concentrated facial delivery; the journal piece on nicotinamide riboside covers precursor pharmacology in depth.

What 10% cream means in practice

A 10% NAD+ cream delivers 100 mg per gram applied. Typical nightly use might apply 0.5 to 1 gram to face and neck, supplying 50 to 100 mg topical NAD+ per session. Compounded pump bottles improve dosing consistency over jar products.

Vehicle matters: hyaluronic acid bases, liposomal encapsulation, and penetration enhancers are common compounding choices to move polar NAD+ past the stratum corneum barrier. Stability is another pharmacy concern, NAD+ is oxidation-sensitive, so packaging and preservative systems affect potency over shelf life.

Evidence landscape

Topical nicotinamide (vitamin B3, the reduced precursor family) has robust RCT support for barrier improvement, sebum regulation, and pigment modulation. Pure NAD+ topical RCTs are fewer. Preclinical skin models show NAD+ replenishment improves UV-stress recovery and fibroblast function. Human cosmeceutical studies often use niacinamide rather than NAD+ directly because of cost and stability, which complicates extrapolation.

Patients should view 10% NAD+ cream as a mechanistically grounded compounded option with strong biochemical rationale and emerging but not definitive clinical trial backing at that exact molecule and concentration.

Who uses topical NAD+

Safety and expectations

Topical NAD+ has low systemic exposure and is generally well tolerated. Irritation is formulation-dependent. Results unfold over 8 to 12 weeks for texture and tone changes, not overnight transformation. Compounded products are not FDA-approved; potency testing is pharmacy-dependent.

CLYR Health offers NAD+ face cream as a preview skin-longevity SKU for patients whose providers determine topical NAD+ fits a supervised wellness plan.